New FDA Validator Rules V1.6 Explained
In this blog, we explore what you need to know about the update to the…
CertaraJanuary 12, 2023
New FDA Requirement to Support Labeling on DDIs in the Pediatric Population
The effects of drug-drug interactions (DDIs) could differ in the pediatric population compared to adults.…
CertaraDecember 21, 2022
The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs
Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform can revolutionize your pharmaceutical organization’s approach to PK/PD…
CertaraDecember 16, 2022
Tips & Tricks for Data Management in Phoenix WinNonlin
Learn some tips & tricks for the Data Wizard, a data management tool in Phoenix,…
CertaraNovember 18, 2022
Tips to Use Phoenix WinNonlin More Efficiently
Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform is the single, interoperable hub for sharing pre-clinical…
CertaraNovember 7, 2022
The Role of PBPK Modeling & Simulation in Infants & Neonates
Many factors make it challenging to obtain adequate pediatric samples for use in drug development…
CertaraNovember 4, 2022
Why you should select your drug formulation before starting clinical studies
Drug developers often rush through the discovery process to get into human testing. Most are…
CertaraOctober 28, 2022
PBPK Modeling & Simulation of Therapeutic Oligonucleotides from Bench to Bedside
Next generation therapeutics Oligonucleotide drugs are unique among therapeutic modalities in that they don’t engage…
CertaraOctober 14, 2022
The Growing Value of Quantitative Systems Pharmacology (QSP)
Gain a foundational understanding of QSP in this 101-level article with examples of QSP applied…
CertaraOctober 7, 2022
Choosing a Clinical Trial Transparency and Disclosure Vendor: Your Complete Checklist
Choosing the right technology and services vendor to support your organization’s transparency and disclosure (T&D)…
CertaraOctober 4, 2022
